SelectQuote (SLQT)
NYSE:SLQT
SLQT Stock Chart & Stats
$0.59
$0.12(2.90%)
At close: 4:00 PM EST
$0.59
$0.12(2.90%)
Day’s Range― - ―
52-Week Range$0.58 - $3.73
Previous CloseN/A
Volume368.25K
Average Volume (3M)1.35M
Market Cap
$104.66M
Enterprise Value$540.30M
Total Cash (Recent Filing)$22.20M
Total Debt (Recent Filing)$457.83M
Price to Earnings (P/E)0.9
Beta1.35
Next Earnings
May 07, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.26
Shares Outstanding176,289,660
10 Day Avg. Volume1,235,600
30 Day Avg. Volume1,349,576
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)0.73
Price to Sales (P/S)0.27
P/FCF Ratio-30.25
Enterprise Value/Market Cap5.16
Enterprise Value/Revenue0.33
Enterprise Value/Gross Profit0.48
Enterprise Value/Ebitda3.31
Forecast
1Y Price Target
$4.00Price Target Upside577.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.12
Revenue Forecast (FY)$1.67B
Bulls Say, Bears Say
Bulls Say
De‑risked Balance Sheet & LiquidityThe new $415M senior secured facility extends debt maturities to 2031, raises revolver capacity and reduces amortization. That materially lowers near‑term refinancing risk, increases peak‑season liquidity and gives management optionality to invest or absorb shocks over multiple years.
Durable Senior Segment EconomicsConsistently high senior margins and strong agent retention/productivity support durable commission economics. High retention and improving productivity mean lower acquisition churn and steadier renewal commissions, underpinning recurring revenue and long‑term profitability in core Medicare channels.
Growing Healthcare Services (SelectRx) With Clinical ImpactRapid SelectRx growth and measurable clinical outcomes create a higher‑value, services‑based revenue stream that diversifies commission reliance. Clinical impact strengthens payer/carrier partnerships and supports multiyear PBM deals, improving predictability and long‑term margin potential for healthcare services.
Bears Say
Inconsistent Cash ConversionCash generation remains modest and volatile; OCF and FCF swung negative in recent years and TTM cash is small versus revenue. Weak, inconsistent cash conversion limits capacity to self‑fund growth, pay down debt or absorb shocks without relying on credit or capital raises over the medium term.
Revenue Sensitivity To Carrier/PBM ActionsMaterial revenue and EBITDA rely on carrier marketing budgets and PBM reimbursement terms. The reported ~$40M headwind shows how quickly commissions and enrollments can shift; this structural dependence creates ongoing downside risk when carriers reallocate spend or reimbursement schedules change.
Listing And Regulatory UncertaintyA formal NYSE compliance notice raises delisting risk and could force shareholder measures or strategic distraction. Coupled with CMS preliminary rate softness and elevated plan terminations, this regulatory and market uncertainty threatens enrollment volumes, carrier economics and long‑term visibility.
SelectQuote News
SLQT FAQ
What was SelectQuote’s price range in the past 12 months?
SelectQuote lowest stock price was $0.58 and its highest was $3.73 in the past 12 months.
What is SelectQuote’s market cap?
SelectQuote’s market cap is $104.66M.
When is SelectQuote’s upcoming earnings report date?
SelectQuote’s upcoming earnings report date is May 07, 2026 which is in 38 days.
How were SelectQuote’s earnings last quarter?
SelectQuote released its earnings results on Feb 05, 2026. The company reported $0.26 earnings per share for the quarter, beating the consensus estimate of $0.218 by $0.042.
Is SelectQuote overvalued?
According to Wall Street analysts SelectQuote’s price is currently Undervalued.
Does SelectQuote pay dividends?
SelectQuote does not currently pay dividends.
What is SelectQuote’s EPS estimate?
SelectQuote’s EPS estimate is >-0.01.
How many shares outstanding does SelectQuote have?
SelectQuote has 176,289,660 shares outstanding.
What happened to SelectQuote’s price movement after its last earnings report?
SelectQuote reported an EPS of $0.26 in its last earnings report, beating expectations of $0.218. Following the earnings report the stock price went down -28.966%.
Which hedge fund is a major shareholder of SelectQuote?
Currently, no hedge funds are holding shares in SLQT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
SelectQuote Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (577.97% Upside)
$4.00 (577.97% Upside)
Blogger Sentiment
Bullish
SLQT Sentiment 66%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 63.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $104.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 8.6%
Last 30 Days ▼ 8.6%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-83.29%
12-Months-Change
Fundamentals
Return on Equity
13.52%
Trailing 12-Months
Asset Growth
5.71%
Trailing 12-Months
Company Description
SelectQuote
SelectQuote, Inc. operates a technology-enabled, direct-to-consumer distribution platform that sells a range of insurance policies to consumers from various insurance carriers in the United States. The company operates through three segments: Senior; Life; and Auto & Home. It distributes senior health policies, such as medicare advantage, medicare supplement, medicare part D, and other ancillary senior health insurance related policies, including prescription drugs, dental, vision, and hearing plans; term life policies; and non-commercial auto and home property, and casualty policies. The company was incorporated in 1999 and is headquartered in Overland Park, Kansas.
SLQT Company Deck
SLQT Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call described strong operational execution: double‑digit consolidated revenue growth, near‑record senior margins (39%), rapid SelectRx revenue growth (26% YoY) and measurable clinical outcomes (20% fewer hospital days). Management secured a multiyear PBM agreement and a $415M credit facility that materially improves visibility and capital flexibility. However, the quarter and fiscal 2026 guidance were meaningfully impacted by two discrete headwinds (~$20M PBM reimbursement adjustment and ~$20M from a national carrier marketing cut), prompting a revised adjusted EBITDA range of $90–$100M and signaling near‑term uncertainty from industry disruption and preliminary CMS rate guidance. Overall the operational and cash flow improvements and strategic balance sheet actions outweigh the near‑term, largely one‑time headwinds, leaving management optimistic about long‑term profitability and cash generation.View all SLQT earnings summariesSLQT Stock 12 Month Forecast
Average Price Target
$4.00
▲(577.97% Upside)
Technical Analysis
Ownership Overview
29.71% Insiders
7.68% Mutual Funds
9.77% Other Institutional Investors
44.05% Public Companies and
Individual Investors